Hikal peers

·Pharma & HealthChart ›

Companies like Hikallatest year

HikalHIKAL · FY26 · this company
Market cap₹2,496
P/E—
Sales growth+5.9%
ROE−4.0%
Panacea BiotecPANACEABIO · FY26
Open ›
Market cap₹2,017
P/E—
Sales growth+19.7%
ROE−0.6%
Dishman Carbogen AmcisDCAL · FY26
Open ›
Market cap₹2,334
P/E23.93×
Sales growth−4.3%
ROE1.6%
Sai ParenteralsSAIPARENT · FY26
Open ›
Market cap₹2,139
P/E111.02×
Sales growth—
ROE2.9%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HIKAL₹202.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,496 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
HIKAL
FY26
PANACEABIO
FY26
DCAL
FY26
SAIPARENT
FY26
Peer
Average
Valuation — at last close
P/E——◆ 23.93×111.02×67.48×
P/B2.08×2.42×◆ 0.35×4.36×2.37× -12%
EV/EBITDA14.35×◆ -420.68×7.25×52.86×-120.19× +112%
Market Cap₹2,496 Cr₹2,017 Cr₹2,334 Cr₹2,139 Cr₹2,163 Cr +15%
Growth
Revenue CAGR 3Y-5.40%◆ 11.63%6.71%—9.17% -159%
Revenue CAGR 5Y-0.09%0.47%◆ 8.93%—4.70% -102%
Revenue YoY (latest Q)5.89%◆ 19.72%-4.29%—7.71% -24%
Net Income YoY (latest Q)◆ 66.96%-44.44%-347.24%—-195.84% +134%
Profitability
EBITDA Margin12.87%-0.73%◆ 19.29%10.16%9.57% +34%
Net Income Margin-2.85%-1.12%3.32%◆ 3.74%1.98% -244%
Return on Common Equity-3.97%-0.64%1.56%◆ 2.91%1.28% -411%
Return on Capital Employed◆ 3.30%-4.11%2.57%2.57%0.34% +861%
Return on Assets-1.99%-0.56%0.89%◆ 1.00%0.44% -549%
Credit & Quality
Total Debt/Equity0.57×◆ 0.03×0.42×0.65×0.37× +55%
Interest Coverage0.91×-6.23×◆ 1.30×1.18×-1.25× +173%
Scale — latest FY
Revenue / Total Income₹1,713 Cr₹640 Cr₹2,932 Cr₹381 Cr₹1,318 Cr +30%
Net Income−₹48.8 Cr−₹7.2 Cr₹97.5 Cr₹14.3 Cr₹34.8 Cr -240%
Total Assets₹2,365 Cr₹1,262 Cr₹11,923 Cr₹1,424 Cr₹4,870 Cr -51%
EPS₹-3.96₹-0.88₹6.22₹4.36₹3.23 -222%
Book Value per Share₹97.07₹136.19₹425.82₹111.08₹224.36 -57%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.